These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35134970)

  • 1. The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
    Tanaka Y; Atsumi T; Okada M; Miyamura T; Ishii T; Nishiyama S; Matsumura R; Hayashi N; Abreu G; Tummala R; Morand EF; Takeuchi T
    Mod Rheumatol; 2023 Jan; 33(1):134-144. PubMed ID: 35134970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
    Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R;
    Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF; Abreu G; Furie RA; Golder V; Tummala R
    Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
    Vital EM; Merrill JT; Morand EF; Furie RA; Bruce IN; Tanaka Y; Manzi S; Kalunian KC; Kalyani RN; Streicher K; Abreu G; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):951-961. PubMed ID: 35338035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis.
    Tanaka Y; Atsumi T; Okada M; Miyamura T; Ishii T; Nishiyama S; Matsumura R; Kawakami A; Hayashi N; Abreu G; Yavuz S; Lindholm C; Al-Mossawi H; Takeuchi T
    Mod Rheumatol; 2024 Jul; 34(4):720-731. PubMed ID: 37706527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
    Chia YL; Zhang J; Tummala R; Rouse T; Furie RA; Morand EF
    Rheumatology (Oxford); 2022 May; 61(5):1900-1910. PubMed ID: 34528084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
    Bruce IN; van Vollenhoven RF; Morand EF; Furie RA; Manzi S; White WB; Abreu G; Tummala R
    Rheumatology (Oxford); 2023 Apr; 62(4):1526-1534. PubMed ID: 36018235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y; Tummala R
    Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
    Furie R; Morand EF; Askanase AD; Vital EM; Merrill JT; Kalyani RN; Abreu G; Pineda L; Tummala R
    Lupus; 2021 Jul; 30(8):1254-1263. PubMed ID: 33977796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab.
    Strand V; O'Quinn S; Furie RA; Morand EF; Kalunian KC; Schwetje EG; Abreu G; Tummala R
    Lancet Rheumatol; 2022 Mar; 4(3):e198-e207. PubMed ID: 38288936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
    Bruce IN; Furie RA; Morand EF; Manzi S; Tanaka Y; Kalunian KC; Merrill JT; Puzio P; Maho E; Kleoudis C; Albulescu M; Hultquist M; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):962-969. PubMed ID: 35580976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
    Kalunian KC; Furie R; Morand EF; Bruce IN; Manzi S; Tanaka Y; Winthrop K; Hupka I; Zhang LJ; Werther S; Abreu G; Hultquist M; Tummala R; Lindholm C; Al-Mossawi H
    Arthritis Rheumatol; 2023 Feb; 75(2):253-265. PubMed ID: 36369793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
    N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
    Morand EF; Furie RA; Bruce IN; Vital EM; Dall'Era M; Maho E; Pineda L; Tummala R
    Lancet Rheumatol; 2022 Apr; 4(4):e282-e292. PubMed ID: 38288923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
    Chia YL; Tummala R; Mai TH; Rouse T; Streicher K; White WI; Morand EF; Furie RA
    J Clin Pharmacol; 2022 Sep; 62(9):1094-1105. PubMed ID: 35352835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.
    Tummala R; Abreu G; Pineda L; Michaels MA; Kalyani RN; Furie RA; Morand EF
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33597205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
    Baker T; Sharifian H; Newcombe PJ; Gavin PG; Lazarus MN; Ramaswamy M; White WI; Ferrari N; Muthas D; Tummala R; Morand EF; Furie RA; Vital EM; Chamberlain C; Platt A; Al-Mossawi H; Brohawn PZ; Csomor E
    Ann Rheum Dis; 2024 Jul; 83(8):1018-1027. PubMed ID: 38569851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.